NPPB and cancer: In the PREVEND study—a community based prospective, observational cohort with 8,592 participants—Meijers et al. discovered over a median follow-up of 11.5 years that higher baseline levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), a key marker for HF severity, correlated with an increased risk of new-onset cancer, even after adjusting for age, smoking, and BMI [13].